CING CINGULATE INC

Cingulate to Present at H.C. Wainwright Global Investment Conference

Cingulate to Present at H.C. Wainwright Global Investment Conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and Chief Executive Officer, Shane J. Schaffer, and Chief Medical Officer, Matthew Brams, M.D., will present a company overview at the on Wednesday, May 25, 2022, from 3:00-3:30 p.m. ET, at the Fontainebleau Miami Beach Hotel, Miami, FL.

A live webcast of the presentation may be accessed at: . A replay will be available on the investor section of Cingulate’s website at for 90 days.

About Cingulate®

Cingulate Inc. (NASDAQ: CING), is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, such as anxiety disorders.

Cingulate is headquartered in Kansas City, KS. For more information visit 

Investor Relations 

Thomas Dalton

Head of Investor & Public Relations, Cingulate, Inc.

(913) 942-2301



Matt Kreps

Darrow Associates

(214) 597-8200

Media Relations

Melyssa Weible

Elixir Health Public Relations

(201) 723-5805



EN
18/05/2022

Underlying

CINGCINGULATE INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CINGULATE INC

 PRESS RELEASE
Free
CING CINGULATE INC

Cingulate Announces the Closing of a $12 Million Private Placement Pri...

Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”). “This long-term financing from life science–focused institutional investors represents strong validation o...

February 17, 2026 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provid...

Cingulate Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update Industry Veteran Bryan Downey Named Chief Commercial Officer NDA Accepted with May 2026 PDUFA Date Commercial Supply Agreement Executed KANSAS CITY, Kan., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to build a pipeline of next-generation products, today announced financial results for the quarter ended September 30, 2025, and provided recent corporate highlights. Rec...

November 13, 2025 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer...

Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301 Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CITY, Kan., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™...

November 10, 2025 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentat...

Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that data from its lead ADHD candidate CTx-1301 (dexmethylphe...

October 23, 2025 1 EN
 PRESS RELEASE
Free
CING CINGULATE INC

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention...

FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention-Deficit/Hyperactivity Disorder (ADHD) and sets a May 31, 2026 PDUFA Date Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the FDA’s 505(b)(2) regulatory pathway KANSAS CITY, Kan., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch